LIXTE Biotechnology Holdings (NASDAQ: LIXT) is making strides in precision oncology with its lead program, LB-100, a novel small-molecule compound designed to improve the effectiveness of chemotherapy and radiation while minimizing damage to healthy tissue. According to a recent article, the company is tackling a persistent challenge in oncology: maximizing treatment impact while reducing risks to patients.
LB-100 is a first-in-class clinical PP2A inhibitor that has shown to be well-tolerated in cancer patients at doses associated with anti-cancer activity. The compound is part of a pioneering effort in a new field of cancer biology known as activation lethality, which represents a new treatment paradigm. Preclinical data, published on the company’s website at www.lixte.com, suggests that LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients.
Proof-of-concept clinical trials are currently underway for ovarian clear cell carcinoma and metastatic colon cancer. These trials aim to demonstrate the compound’s ability to improve the therapeutic index of existing cancer modalities, a key goal in oncology research. The company’s approach is protected by a comprehensive patent portfolio, covering its novel use of PP2A inhibition in cancer treatment.
The announcement highlights LIXTE’s focus on precision oncology, integrating cutting-edge data solutions to develop therapies that complement existing treatments. By enhancing the efficacy of standard therapies, LB-100 could offer new options for patients with difficult-to-treat cancers. The full article detailing these developments is available at https://ibn.fm/EE6ya.
LIXTE Biotechnology Holdings Inc. is a clinical-stage pharmaceutical company based in Los Angeles, California. The company is dedicated to developing and commercializing cancer therapies, with a focus on new targets for drug development. Its lead compound, LB-100, represents a novel approach in cancer treatment, aiming to improve patient outcomes by making existing therapies more effective and less toxic.
The company cautions that forward-looking statements in the announcement involve risks and uncertainties, as detailed in its filings with the Securities and Exchange Commission. Investors are advised not to place undue reliance on these statements, as actual results may differ materially from those projected.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100.